Objectives To assess the extent of use, patterns, variables and Adverse Drug Reactions associated with off label prescribing in Pediatrics. Methods A prospective observational study was conducted for a period of 6 months for children of the age group 0-17 years in a tertiary care Hospital in Maharashtra, India. Off label drug use was assessed using Micromedex and British National Formulary for Children (BNFC 2016(BNFC -2017. Adverse Drug Reactions (ADRs) were assessed according to the physicians' notes, recorded during the patient's hospital stay. Pearson correlation coefficient was computed to assess the relationship between age and the number of offlabel drugs. Odds ratio was calculated for the occurrence of ADRs in on-label prescriptions Vs off label-prescriptions. A P value of <0.05 was considered as significant. Key findings A total of 1514 prescriptions were evaluated in 300 patients. Out of which 542 (35.79%) and 423 (27.9%) were off label according to Micromedex and BNFC respectively. The number of patients who received at least one off label was found to be 225 (75%) -Micromedex and 223 (74.3%) -BNFC Unspecified indication and use of drugs outside the specified age limit were identified as the main variables associated with off label prescribing. Highest proportion of off-label drugs was found in Alimentary system. A total of 35 ADRs (OR 6.92 CI 95%(OR 6.92, 95% CI, 3.13-15.27)) were identified in 31 patients. Conclusions Off-label drug use is prevalent in the pediatric population and warrants an evidence-based approach to improve prescribing practices in pediatrics.
Introduction
The term off label has a lot of stigma associated with it as it implies using medicines outside their labelled specifications. Off-label use' implicates the use of drugs in a manner that is not listed in the product leaflet with respect to its indication, age category, and dose or administration route. It does not imply an improper, illegal, contraindicated or investigational use. In India, the pediatric population often has to receive off labelled medicines as part of regular therapy due to lack of approved drugs for the specified indications. The European Medicines Agency (EMA), Food and Drug Administration of the United States of America (FDA), Central Drugs Standard Control Organization (CDSCO) of India and other regulatory agencies, are responsible for ensuring the quality, safety and efficacy of the drug and its compliance with the approved guidelines. However, such authorities do not generally regulate the administration of drugs in day to day practice, hence off label prescribing is highly prevalent in pediatric medical practice. [1] Despite many regulatory amendments in pediatric drug development, the number of clinical trials in pediatrics is still very scarce as compared to adults, which has resulted in the use of medicines in a manner which is inconsistent with its approved product license. [2] The key to achieving ideal pediatric drug therapy lies in understanding that the pharmacokinetic and pharmacodynamics characteristics alter over a child's development from infancy to adulthood. To consider pediatric patients as small adults and make therapeutic decisions based on this assumption would be a gross error in judgment. [3] It has been reported that Adverse drug reactions (ADRs) in children have a relatively more severe effect when compared to adults as they result in hospital admissions or prolonged hospitalization which may lead to permanent disability or even death. [4] [5] [6] The frequency, severity and types of drugs most frequently involved in adverse reactions is of particular interest in pediatrics, since pre-marketing clinical trials are done mostly in adults. Studies on off-label drug use are most commonly focused on magnitude of off label prescribing rather than associated risks. Bellis et al. found that off-label medicines are more likely to be implicated for ADRs. [7] Currently, there is distinct lack of research to evaluate ADRs associated with off-label medicines especially in developing countries like India.
Due to the increasing need to generate quality data on the off label use of medicines in the pediatric population and facilitate ideal prescribing practises, our study aims at assessing the extent of use, patterns, factors and adverse drug reactions associated with off label prescribing in pediatric population.
Method
This study was a prospective observational study carried out for 6 months (September-2017 to February-2018) at a tertiary care hospital in Pune, Maharashtra. Patients from age 0 to 17 admitted in the general pediatric ward, pediatric intensive care unit and high dependency unit were included in the study while pediatric surgery, oncology and out patients were excluded. A feasibility study of 2 weeks was performed to ascertain the extent of off label use and gauge the required sample size. The study protocol was approved by the Institutional Ethics Committee of Bharati Vidyapeeth Deemed University Medical College (REF: BVDUMC/IEC/85).
The British National Formulary for Children 2016-2017 was used as a tertiary reference source and Micromedex was used as a secondary reference database to identify and assess off label and unlicensed use. Off label use was categorized into the following variables: Age (drug use outside the approved age group), indication (drug used for a non-FDA approved/Non-BNFC specified indication), dose (higher or lower than recommended) and route of administration (drug administered by a nonapproved route). Drugs were classified into the above mentioned variables following the pattern as shown in Figure 1 . A drug could be classified as off label under more than one category. Prescriptions were classified as unlicensed if it was specified as 'unlicensed for use in children' in the BNFC (e.g. Ketorolac) or if it was mentioned as 'safety and efficacy not established' in Micromedex (e.g. Pantoprazole). Certain drugs were not available in either of the reference databases hence were classified as not available (e.g. Domperidone). Prescriptions containing formulations of electrolytes, vitamins B and C, nutritional supplements, standard intravenous replacement solutions, topical lotions, creams and ointments and Ayurvedic preparations were considered as non evaluable. The Anatomical Therapeutic Chemical Classification (ATC) code of each drug was recorded according to the WHO Collaborating Center for Drug Statistics Methodology. ADRs were assessed according to the physicians' notes recorded during the patient's entire hospital stay. Any new, nondisease-related symptom observed in the patient such as diarrhoea, vomiting, rash, thrombophlebitis or other diarrhoea, nausea, vomiting or any biochemistry changes were evaluated and classified according to Wills and Brown classification of ADRs.
Statistical analysis
A Pearson correlation coefficient (r) was computed to assess the relationship between age and the number of off-label drugs as per Micromedex and BNFC 2016-2017. Odds ratio (OR) was calculated for the occurrence of ADRs in on-label prescriptions Vs off-label prescriptions with 95% confidence interval (CI). A P value of <0.05 was considered as significant.
Result Demographic details and summary of prescriptions analysed
In a period of 6 months, a total of 300 patients were included in the study, out of which 183 were male and 117 were female. The age range of the patients was 0-17 years with a mean age of 3.5 and standard error 0.2360. The age wise classification of patients is presented in Table 1 . A total of 300 patients were prescribed with 1883 number of prescriptions. The average number of prescriptions for the age group 0-30 days was 11.5 and for the rest of the age groups was 4.93.
Extent of off label use
Out of the total number of prescriptions, 1514 prescriptions were considered as evaluable according to the study criteria, out of which, 542 (35.79%) were considered as off label based on the Micromedex database and 423(27.9%) were considered as off label based on BNFC 2016-2017. A total of 225 (75%) of the patients received at least one off-label prescription according to Micromedex and 223 (74.3%) received at least one off-label medicines as per BNFC. The unlicensed prescriptions according to Micromedex and BNFC were found to be 144 (9.5%) and 71 (4.68%) respectively.
Variables of off label use
The most common variable associated with off label use according to Micromedex was found to be age in the age group of 0-2 years and for indication in the age group 3-17 years and that according to BNFC was found to be indication for the age groups 1-17 years and for age in the 0-30 day age group as shown in Table 2 . There was a negative correlation between age and the number of off-label drugs as per Micromedex which was statistically significant (r = À0.1848, P = 0.0012), while no correlation was observed between age and number of off-label drugs as per BNFC (r = À0.0018, P = 0.9742).
Off label prescribing by ATC class as per Micromedex and BNFC
According to Micromedex, highest proportions of off-label drugs were prescribed in Respiratory System 175 and Alimentary System 146 as shown in Figure 2 , which included Salbutamol, Ipratropium bromide, Ondansetron and Lansoprazole. As per BNFC, highest proportions of offlabel drugs were found in Alimentary system 136 and Antiinfectives 119 as shown in Figure 3 which included Ceftriaxone and Piperacillin-tazobactam. The most commonly prescribed drugs were Paracetamol, Ondansetron and Ceftriaxone out of which Ondansetron showed highest off label prescribing, according to both Micromedex and BNFC. The examples of off label use as per BNFC and Micromedex are described in Table 3 .
ADRs associated with off label and On label prescribing A total of 35 ADRs were reported in 31 of the 300 patients. The ADRs seen were as follows: diarrhoea 12 (34%), vomiting 10 (29%), rashes 6 (17%), thrombophlebitis 3 (8%), anaemia 2 (6%), increased creatinine level 1 (3%) and dysrhythmias1 (3%). It was found that the odds of ADR occurrence with on-label drugs were higher than with off-label drugs (OR 6.92, CI 3.13 to 15.27). The most common ADRs were found to be of the types -A (Augmented), B (Bugs/Bizzare), C (Chemical), D (Delivery), H (Hypersensitivity) and U (Unclassified) according to the Wills and Brown Classification as shown in Table 4 .
Discussion
Our study aimed at analysing the proportion of off label and unlicensed drug use based on BNFC and Micromedex database and finding out the pattern, extent and ADRs associated with Off-label prescribing of off-label prescribing. These two databases were selected as Micromedex is known n, total number of off-label drugs. Numbers in brackets represent percentages. for Micromedex is a well known source that provides easy access to a large amount of FDA approved data and the BNFC is a standard compendia used by physicians across the globe. The mean age of the population in our study was lesser than that seen in other studies based on Off-label drug use in pediatrics in India. [8, 9] This could be attributed to the fact that a large proportion of the total patients enrolled in the current study were in the age group 1 month-2 years as compared to the number of patients enrolled in age groups 2-12 years due to the higher frequency of diseases such as upper and lower respiratory tract infections, seizure disorders and acute gastroenteritis occurring in this population. A study published by Bhadiyadara et al. reported that out of 405 drugs, 10.1% drugs were used in an off label manner as per BNFC-2012. [9] Though their study was comparable to a previous outpatient study reported a decade back from UK which showed 10.5% offlabel prescription according to BNFC-1998, [10] our study Figure 2 Off-label drugs as per ATC system according to Micromedex. identified a higher proportion of off-label drugs (27.9%) as per BNFC 2016-2017, which suggests the improvement in quality of the database due to periodic editions that reflect ever emerging clinical practices. Turner et al., studied drug use conditions in a PICU, published that 70% of the total patients received at least one off label drug and their percentages are similar to the findings of our study. [11] In a study conducted in a Swiss Pediatric hospital, unlicensed medicines were subdivided into three classes: (1) medicines prepared or modified by the hospital pharmacy (batch or extemporaneous preparations); (2) medicines prepared by authorized manufacturers especially for Swiss hospitals; and (3) medicines imported from a foreign country. However, in our study, we have considered unlicensed medicines as those for which safety and efficacy are not established and those which are specified as unlicensed in the BNFC. Therefore, the unlicensed prescriptions identified in our study were considerably less as compared to that found in the Swiss Pediatric Hospital which was 24%. [12] A literature review by Pandolfini and Bonati reported that 32-92% of children received at least one off label or unlicensed drug for which the most common reasons were dosage and patient's age, followed by indication. [13] However, our study showed a higher proportion of off label use due to age and indication rather than dose. This difference may be due to several reasons: such as difference in medical conditions and associated prescription practices across different geographical areas, disparity among references used in each study to evaluate drug use conditions or even changes in the methodology of each study. According to a study by Garcia Lopez et al., a lineal tendency between age and off label drug use was observed where off label use increased as patients age decreased, which was similar to the result found as per Micromedex in the present study. [14] Mohd Masnoon Saiyed et al. stratified the off label medicine use by ATC class and reported that the highest proportion was prescribed in anti-infectives for systemic use (73%) and respiratory system (82%) which is comparable to our study. [2] A stark similarity between our study and the other studies on is that salbutamol and ondansetron are often prescribed in an off label way. [2, 9, 13, 15] Manufacturers of these drugs must take note of these studies so as to bring about a change in their labelling specifications. Three studies report paracetamol to be off label for age and dose whereas no prescription of paracetamol was considered as off label in our study as it was found to be prescribed according to labelled dose and age specifications. [2, 9, 16] Though standardized pediatric textbooks and local guidelines indicate the use of many drugs in pediatrics as per a particular age, indication, dose and route for specific diseases, it has been found through our study that these uses are not reflected in the BNFC and Micromedex. Thus, more safety and efficacy data must be generated so as to bring about an evidenced based change in label specifications that would facilitate a completely safe drug use in the pediatric population. It was found through our study that there was no correlation between the occurrence of ADRs and off label drug use as ADRs associated with off label drug use was lesser than that caused by on-label drug use. There were also no differences in severity between ADRs caused by on-label and off-label drugs The Wills and Browns classification is an efficient system to distinguish between commonly occurring, predictable, reactions related to the pharmacological action of the drug which are usually dose dependent (Type A reactions) and reactions that occur less commonly and mostly are unrelated to known pharmacological action of the drug (Type B reactions). [17] Since most of the ADRs that occurred in the present study were of mild to moderate severity, it was befitting to classify the ADRs according to the nine categories (Augmented, Bugs, Chemical, Delivery, Exit, Familial, Genotoxicity, Hypersensitivity and Unclassified) so as to enhance the clarity of the probable mechanisms by which the ADRs occurred. The labels of the frequently prescribed off-label drugs must be updated, so as to bring about a paradigm shift from off label prescribing.
Limitations
Databases used to identify off label drug use in our Indian hospital setting were Micromedex and BNFC 2016-2017. Though the National Formulary of India (NFI) is available as a manual containing clinically oriented summaries of pharmacological information about selected drugs, it was not used as a reference database in our study due to the lesser availability of pediatric-specific information. The study was a single center study with a smaller sample size. ADRs were identified based on the physicians notes which may include subjective bias.
Conclusion
Our study revealed that off label prescribing is prevalent in pediatric inpatient practice. Unspecified indication and use of drugs outside the specified age limit were identified as the main variables associated with off label prescribing. From safety outlook, physicians prescribing for pediatric population should be vigilant for the occurrence of ADRs irrespective of on label or off label use. Off label prescribing will require a drastic effort from all parts of the medication use chain that is, manufacturers, doctors, nurses and patients so as to ensure complete safety and efficacy of drugs. Improving the quality of commonly used compendia to reflect real evidence based data is the only way to significantly improve rationality of pediatric pharmacotherapy.
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